Director Daniel Janney of Krystal Biotech, Inc. (NASDAQ:KRYS) reported the sale of 11,803 shares of common stock on February 27, 2026, in a Form 4 filing with the Securities and Exchange Commission. The disposition was carried out under a Rule 10b5-1 trading plan and produced proceeds totaling $3.25 million.
The transactions were recorded as two separate sales. The first sale comprised 9,430 shares at a weighted average price of $275.4487, generating $2,597,405 in proceeds. Those shares were sold across multiple trades with executed prices that ranged from $275.00 to $275.986. The second sale included 2,373 shares at a weighted average price of $276.1665, for total proceeds of $655,419; the individual trades in that lot had prices ranging from $276.00 to $276.4924.
Following these reported transactions, Janney directly beneficially owns 73,293 shares of Krystal Biotech common stock through Alta Bioequities, L.P., according to the filing.
Market context in the filing notes that Krystal Biotech shares have risen 54% over the past year and 76% in the last six months, based on InvestingPro data. At the time of the filing the company was trading at $263.77 and carried a market capitalization of $7.77 billion. InvestingPro analysis cited in the filing indicates the stock is slightly undervalued and mentions that 15 additional ProTips are available to subscribers.
Separately, Krystal Biotech reported fourth-quarter 2025 financial results that outperformed analyst expectations. The company posted earnings per share of $1.70, above the forecasted $1.58. Revenue for the quarter was $107.1 million, beating the anticipated $106.16 million. The filing states that these figures underscore the companys strong performance during the period and that the earnings announcement has been well-received by investors.
The Form 4 filing and related disclosures note that there were no recent updates regarding mergers or acquisitions. It also states that analyst firms have not issued recent upgrades or downgrades for Krystal Biotech, and that there have been no other significant company announcements or developments disclosed.
Key points
- Director Daniel Janney sold 11,803 shares on February 27, 2026, via a Rule 10b5-1 plan, generating $3.25 million.
- Krystal reported Q4 2025 EPS of $1.70 and revenue of $107.1 million, both above consensus estimates.
- Shares have climbed 54% over the past year and 76% in the last six months; market price reported at $263.77 with a $7.77 billion market cap.
Risks and uncertainties
- No recent mergers or acquisitions were reported - the company has not disclosed activity in this area.
- There have been no recent analyst upgrades or downgrades, leaving external coverage unchanged.
- The company disclosed no other significant announcements or developments in the filing.
This article presents the transaction and the company disclosures as reported in the SEC filing and related company results; it does not add or interpret information beyond what was reported.